Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A recent study links diabetes to advanced liver damage in people with HIV.
If passed, the law would boost liver disease research and create a national strategy to tackle non-alcoholic steatohepatitis.
Fat in the liver can lead to health complications, including cirrhosis and liver cancer.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
A recent study also found that having a higher body mass index was associated with a higher risk of fatty liver disease.
Twelve states have an adult obesity prevalence of 35% or more.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.
The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.
Non-alcoholic fatty liver disease is more common among those with the virus compared with the general population.
Non-alcoholic steatohepatitis, the more severe form of non-alcoholic fatty liver disease, is highly prevalent in the HIV population.
A recent study found one in five people with HIV should be assessed for fatty liver, and 1 in 10 should be referred to a liver specialist.
Gastrointestinal cancers conference emphasizes patient quality of life.
Researchers call for greater use of noninvasive measures of fatty liver disease in this population to identify those at risk.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.